ADMA Stock — ADMA Biologics, Inc.

ADMA Biologics, Inc. (ADMA)

Updated October 16, 2026.

ADMA is a Stock. Total return is 24.9% over the past 13 years, 423.3 points behind SPY at 448.2%.

ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases. Its marketed products include BIVIGAM and ASCENIV, intravenous immune globulins for primary immunodeficiency, and Nabi-HB for hepatitis B exposure, along with a pipeline of additional plasma-derived therapeutics; the company also operates source plasma collection facilities. The company does not currently have an established distribution schedule.

ADMA performance versus SPY

Price and return data through 2026-10-16.

Total return is 24.9% over the past 13 years, 423.3 points behind SPY at 448.2%. Over the past year its total return — price change plus distributions reinvested — is -26.6%. Its deepest 1-year drawdown was 62.7%.

ADMA key facts

Asset type

Stock

Asset class

Equity

Inception date

10/17/2013

Distribution frequency

None

Last close

$10.68 (as of 2026-10-16)

Market cap

$2,392,156,382

Average volume

3073663.0

Beta

0.694

Payout ratio

0.0%

P/E ratio

15.26

Forward P/E

9.7847

EPS

$0.70

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ADMA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 62.7%.

Who may consider ADMA — and who may not

It is a weaker fit for investors who need monthly cash flow (ADMA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ADMA

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions